Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10605951rdf:typepubmed:Citationlld:pubmed
pubmed-article:10605951lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:10605951lifeskim:mentionsumls-concept:C0032176lld:lifeskim
pubmed-article:10605951lifeskim:mentionsumls-concept:C0010592lld:lifeskim
pubmed-article:10605951lifeskim:mentionsumls-concept:C0205100lld:lifeskim
pubmed-article:10605951lifeskim:mentionsumls-concept:C0857121lld:lifeskim
pubmed-article:10605951pubmed:issue5lld:pubmed
pubmed-article:10605951pubmed:dateCreated2000-3-1lld:pubmed
pubmed-article:10605951pubmed:abstractTextCyclosporin A plays an important role in preventing rejection in allograft transplant recipients. However, the therapeutic use of cyclosporin A is associated with increased incidence of thromboembolic complications and drug-related hypertension. In order to study the mechanisms by which cyclosporin A induces these abnormal pathophysiological situations, we have assessed the platelet serotonin contents and whole blood platelet aggregation in control rats as well as in rats treated (orally) with 30 and 5 mg/kg/day of cyclosporin A, after 2 and 7 weeks of treatment. These doses correspond respectively to CsA "peak" and "trough" concentrations achieved in human blood in clinical practice (immediately following an intake of a daily dose of CsA and when the blood concentration stabilizes, respectively). Both trough and peak doses caused an increase in blood pressure after 2 and 7 weeks. Platelet serotonin content decreased in the cyclosporin-treated groups, in contrast with the control. Collagen-induced whole blood platelet aggregation increased drastically for the peak concentration-treated group, while adenosine 5'-diphosphate-induced platelet aggregation did not reach statistical significance. Finally, in vitro platelet thromboxane A2 generation increased in cyclosporin A concentrations when platelets were stimulated with either collagen or adenosine 5'-diphosphate. In conclusion, both tested cyclosporin A concentrations induced important changes in platelet serotonin and thromboxane content and aggregation, factors which may play a decisive role in the development and/or maintenance of hypertension and thrombotic complications.lld:pubmed
pubmed-article:10605951pubmed:languageenglld:pubmed
pubmed-article:10605951pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10605951pubmed:citationSubsetIMlld:pubmed
pubmed-article:10605951pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10605951pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10605951pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10605951pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10605951pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10605951pubmed:statusMEDLINElld:pubmed
pubmed-article:10605951pubmed:monthDeclld:pubmed
pubmed-article:10605951pubmed:issn0049-3848lld:pubmed
pubmed-article:10605951pubmed:authorpubmed-author:TeixeiraFFlld:pubmed
pubmed-article:10605951pubmed:authorpubmed-author:ReisFFlld:pubmed
pubmed-article:10605951pubmed:authorpubmed-author:TavaresPPlld:pubmed
pubmed-article:10605951pubmed:authorpubmed-author:AntunesFFlld:pubmed
pubmed-article:10605951pubmed:authorpubmed-author:Fontes...lld:pubmed
pubmed-article:10605951pubmed:issnTypePrintlld:pubmed
pubmed-article:10605951pubmed:day1lld:pubmed
pubmed-article:10605951pubmed:volume96lld:pubmed
pubmed-article:10605951pubmed:ownerNLMlld:pubmed
pubmed-article:10605951pubmed:authorsCompleteYlld:pubmed
pubmed-article:10605951pubmed:pagination365-72lld:pubmed
pubmed-article:10605951pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:meshHeadingpubmed-meshheading:10605951...lld:pubmed
pubmed-article:10605951pubmed:year1999lld:pubmed
pubmed-article:10605951pubmed:articleTitleThe peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats.lld:pubmed
pubmed-article:10605951pubmed:affiliationInstitute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Universidade de Coimbra, Portugal.lld:pubmed
pubmed-article:10605951pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10605951pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10605951lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10605951lld:pubmed